Catalyst Pharmaceuticals (CPRX - Free Report) stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for …
ZACKS10mon
The stock was up nearly 7% to $1.05 Monday on news of the SPA, but closed on Wednesday at $0.97, down 7%. It is down 71% for the year. The four analysts covering CPRX assign the stock a rating of Outperform, …
Agreement
Catyalyst Pharmaceutical (NASDAQ: CPRX) intends to offer shares of its common stock in a public offering. Catalyst also expects to grant the underwriters a 30-day option to purchase additional shares of its common …
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. Too many investors have a fundamental misunderstanding about the significance of …
Stock
CPRX). The position is passive by nature and amasses 3.50 million shares, which represent 5.1% of the …
Stock-Callers.com today presents the following Generic Drugs equities for assessment: Catalyst …
The Business
Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock was boosted to a Overweight by stock analysts at PiperJaffray, who have a TP of $4.00 on CPRX. The firm’s Neutral rating is no longer valid. About 15.59 million …
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)‘s stock had its “buy” rating reissued by equities researchers at Roth Capital in a report issued on Friday. They presently have a $2.50 price objective on the …
BNS4mon
What is more, this is the least CPRX could lose considering that at times the stock was traded around $0.93-$0.95 per share, easily a new 52-week low. This has in turn unleashed the second implication – a wave of …
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)‘s stock had its “buy” rating reissued by equities research analysts at Roth Capital in a research report issued to clients and investors on Friday. They currently …